bi symposium: erfüllung strenger berichtspflichten mit flexiblen, hochadaptiven...
DESCRIPTION
Erfüllung strenger Berichtspflichten mit flexiblen, hochadaptiven Controllingwerkzeugen – Integration des internen und externen Berichtswesens bei BiotestTRANSCRIPT
Biotest AG Company Presentation EU 0
May 2013
Biotest AG Company Presentation
Disclaimer
• This document contains forward-looking statements on overall economic development as
well as on the business, earnings, financial and asset situation of Biotest AG and its
subsidiaries. These statements are based on current plans, estimates, forecasts and
expectations of the company and thus are subject to risks and elements of uncertainty
that could result in deviation of actual developments from expected developments.
• The forward-looking statements are only valid at the time of publication. Biotest does not
intend to update the forward-looking statements and assumes no obligation to do so.
• All figures reported relate to the Continuing Operations of the Biotest Group. After the sale
of the Medical Diagnostic activities to Bio-Rad Laboratories Inc. and the sale of the
segment Microbiological Monitoring to Merck KGaA, both activities are being reported as
Discontinued Operation
• All comparative figures relate to the corresponding last year´s period, unless stated
otherwise.
• The information contained herein serves information purposes and does not constitute
any offer for sale or subscription of or solicitation or invitation of any offer to buy or
subscribe for any securities. In case of a future offering it should be noted that such
offered securities will solely be offered on the basis of an approved securities prospectus.
Any investment decision should only be made based on the information contained in such
prospectus.
Company Presentation EU 1 Biotest AG
Headquarter in Dreieich/Germany
(Frankfurt area)
Subsidiaries in 11 countries worldwide
Employees (FTE)*: 1,834
Thereof 48% located outside Germany
Founded in 1946, IPO in 1987, SDAX in 2007
(preference shares)
Biotest shares:
6,595,242 ordinary shares
6,595,242 preference shares
*: as of June 30, 2013
Biotest Group
Headquarter, Dreieich
Biotest AG Company Presentation EU 2
Shareholder structure
Biotest AG Company Presentation EU 3
Biotest AG
Preference shares: 6.6 mio no voting rights, but higher dividend
Free Float: 100%
Ordinary shares: 6.6 mio with voting rights
OGEL GmbH*: 50.03%
KSK Biberach*: ~24%
Free Float: ~26%
50.0% of total capital,
0% of voting rights
50.0% of total capital,
and 100% of voting rights
* as of June 2013 based on notifications
Biotest: History and milestones achieved
Biotest AG Company Presentation EU 4
1946: Biotest-
Serum Institut
GmbH
1946 2013
1948:
Test-Serum
Anti-D
1961: New
production
facility at
Dreieich 1968: First
subsidiary
outside
Germany
(Italy)
1971: Market
launch of
Intraglobin®
1991: Start of
Microbiological
Monitoring
1987: IPO
2004: Start of
modernized
Plasma Proteins
production
2007:
- Clinical testing of
monoclonal antibodies
- Acquisition of Nabi
- Preference share in SDAX
2010: Divestment of
Medical Diagnostics
2011:
- Divestment of
Microbiological Monitoring
- Biotest- AbbVie
Deal for BT 061
2012: Bivigam®
Launch in US
From plasma to a medicinal product
Biotest AG Company Presentation EU 5
§ § §
Plasma
Donation
Frac-
tionation Purification
Filling &
Packaging
Coagulation Factors
Immunoglobulins
Hyperimmunoglobulins
Human Albumin
Safety - Quality
Supervised and regulated by v. Paul-Ehrlich Institut, FDA etc.
Products
• effective
• safe
• natural
Biotest production sites
Biotest AG Company Presentation EU 6
Production site Dreieich Production site Florida, USA
Biotest produces in Dreieich (near Frankfurt) and in Boca Raton, Florida,USA
1.800 employees worldwide
CapEx per year: approx. € 35 Mio.
Three strategic areas of therapy: Products - Pipeline
7
Haematology Clinical
Immunology Intensive Care
Company Presentation EU Biotest AG
Products
Haemoctin®
Haemonine®
Pipeline
BT-062
Intratect®
Hepatect® , Nabi-HB®
Zutectra®
Cytotect®
Varitect®
Bivigam ®
Fovepta®
Civacir®
Cytotect 70 (BT-094)
Tregalizumab (BT-061)
Pentaglobin®
Humanalbumine
Biseko®
Cofact®
IgM-Concentrate
Fibrinogen
0
100
200
300
400
500
1 2 3 4 5 6 7 8 9
Continue and accelerate growth
8
Biotest Group: Sales 2004-2012 (€ million)*
2004 2005 2006 2007 2008 2009 2010 2011 2012
141.9
339.4
440.0
Sales target
for 2020:
~ € 1 billion
* On a comparable basis, only pharmaceutical activities
Biotest AG Company Presentation EU
Biotest guidance in 2013
422 440
0
100
200
300
400
500
2011 2012 2013e
(EURm)
Biotest AG Company Presentation EU 9
+10-15%
+4.3%
Sales growth 10 – 15% vs. 2012 EBIT growth 10 – 15% vs. 2012
41,6 44,7
0
20
40
60
2011 2012 2013e
(EURm)
+7.5%
+10-15%
Very strong balance sheet and share performance
10
With the successful capital
increase Biotest is well prepared
for new investments in expanding
our capacity
High equity portion of 61% allows
a high debt capacity
Higher number of shares
outstanding and new investors
should lead to an increased
liquidity in our shares
Biotest AG Company Presentation EU
Share price preference shares
+ 64.8% in one
year
Sources: Handelsblatt.com 12.09.2013
Biotest AG 11
Addresses of group figures – internal and external
• Bank Analysts
• Investors
• Shareholders
• Banks
• Supervisory Board
• Management Board
Company Presentation EU
Biotest AG 12
Challenges in reporting
• Harmonisation of the external and internal
reporting
• One database of all departments
• Different IT-Structure in 16 subsidiaries in 11
countries
• Preparation for increasing M&A transactions in
the future
Company Presentation EU
Time Schedule
Biotest AG Company Presentation EU 13
Q1 Q3 Q2 Q1 Q4 Q3 Q4 Q2
2013 2012
Requirements Specification
Proof-of-Concept
Detail-IT-Conception
Implementation SalesTool
Implementation Leg. Consolidation
Implementation Mgmt-Tool
Analysis Mgmt-Reporting
Starting GoLive Step-by-Step
Reqiurements Financial Consolidation
Decision Softwaretool Kick-off Project
As-is Analysis Review Process
Software-Selection
User Requirements
Functional Design
Go Live
Zielarchitektur für Controlling und Finance
Biotest AG Company Presentation EU 14
Oberfläche
(User-Interface) Mobiles
Reporting
Standard-
/Hochglanz-
Reporting Ad-Hoc-Abfragen
„Listen“,
progr. Abfragen
Dashboards,
Cockpits
Basis für eine
erfolgreiche und
nachhaltige
Unternehmens-
steuerung
Gemeinsamen Datenbasis aller Controlling und Finance Daten aus allen Biotest BGs
Controlling Finance/
Konsolidierung
(Unternehmens)Planung
(Sales, Budget, Finance, …)
Operative
Systeme und
Prozesse
der BGs SAP ECC 6.0 SAP R/3 4.7 Non-SAP
Automatische Datenübernahme
XLS-Upload/ Man.Eingabe
FlatFile Upload
Modell Legale Konsolidierung
Biotest AG Company Presentation EU 15
Anbindung der operativen SAP-Systeme
Biotest AG Company Presentation EU 17
FI-GL
CO-PA
Dreieich CO-PA
Reporting
Pre-
Consolidation
Cube
BPC- Cube
/CPMB/CONSOLIDATION
CO-PA
Agregations
Cube
SAP
ERP
SAP BW SAP BPC
CO-PA
Reporting
CO-PA
Mapping
Cube CO-PA
BGs
FI-GL
Agregations
Cube
FI
Mapping
Cube
MAPPING ERP to
SAP BPC
FI-Bilanz
Reporting
Manuelle Erfassungslayouts
• Transparente Datenerfassung für Non-SAP Gesellschaften
• Anwendungsfreundliche und bekannte Benutzeroberfläche
• Nachvollziehbare Datenanpassungen
• Flexible Anpassungen bei neuen Strukturen oder neune gesetzlichen Anforderungen
Biotest AG Company Presentation EU 18
Lessons learned
• Abstimmung und Vereinheitlichung der Abschlussprozesse
• Definition einheitlicher Kennzahlen
• Operative Buchungsvorschriften für Detailauswertungen
• Anwenderfreundlichkeit
• Transparente und revisonssichere Prozesse
• Testvorgehen / Aufsatzpunkt Nachfahren der Altabschlüsse
Biotest AG Company Presentation EU 19
Haben Sie Fragen?
Biotest AG Company Presentation EU 20
Contact
Biotest AG:
Dirk Neumüller
Director Group Reporting
Phone: +49 (0) 6103 - 801 -269
E-Mail: [email protected]
21 Biotest AG Company Presentation EU
IBsolution GmbH:
Thomas Eichelbaum
Project Manager
Phone: +49 (0) 7131 - 2711 -1087
E-Mail: [email protected]